PM493. Interactions of tardive dyskinesia with cognitive function in patients with schizophrenia: worsening of working memory with clozapine treatment
S. Kim,M. Lee,K. Jayathilake,H. Meltzer
DOI: https://doi.org/10.1093/ijnp/pyw041.493
2016-05-27
Abstract:Background : Group I metabotropic glutamate receptor (mGluR1 and mGluR5) allosteric modulators are currently being inves-tigated as novel therapeutics for the treatment of neurodevelopmental disorders such as schizophrenia, autism, depression 2011). Recent evidence suggests that allosteric modulators have adverse pharmacological effects when bound to the monomeric, compared to the dimeric form of these receptors (El Moustaine et al., 2012). Investigating the neurodevelopmental expression of dimeric and monomeric mGluR1 and mGluR5 may highlight possible implications for novel therapeutics at critical neurodevelopmental periods. Methods: Pregnant Sprague-Dawley rats were obtained at gesta-tional day 14. Offspring were euthanised on postnatal day (PN) 12, 35 and 96 (n=6/group) coinciding with juvenile, adolescent and adult time points. Immunoblots were performed on pre-frontal cortex (PFC) and hippocampal tissue under non-reduc-ing conditions to measure dimeric and monomeric mGluR1 and mGluR5 proteins. Results: Dimeric mGluR1and mGluR5 was expressed in higher abundance than their monomeric forms. mGluR1 dimeric expression was lowest at PN12 in both the PFC and hippocampus; where it displayed an increase with age. Whilst monomeric mGluR1 expression was considerably lower, it showed a similar trend in the PFC, however, its expression remained constant in the hippocampus. In contrast, dimeric mGluR5 protein expression in the PFC peaked at PN12 and decreased throughout the neurodevelopmental time-points, however its expression in the hippocampus remained constant throughout. Interestingly, in both regions mGluR5 monomer was highly expressed at PN12, almost equal to dimeric expression and then declined to the lowest limits of detection at later time-points. Conclusion: The monomeric form of mGluR5 is relatively abun-dant during early post-natal development. Considering positive allosteric modulators exert an unregulated agonist effect when bound to the monomeric form of mGluRs, administration of these compounds during such a critical neurodevelopmental period, may cause seizures and neurotoxic effects, posing possible consequences for novel mGluR5 therapeutics. Abstract To obtain insight into abnormalities in neurodevelopmental tra-jectories of schizophrenia, analyses of patient-derived human induced pluripotent stem cells (hiPSCs) be informative. Given the extreme complexity and heterogeneity of genomic architecture underlying ‘general schizophrenia’, analyses of schizophrenia patients with the 22q11.2 deletion could be ben-eficial because the deletion is one of the highest risk factors. We established hiPSCs from two schizophrenia patients with the 22q11.2 deletion and three controls. Neurosphere size, neural differentiation efficiency, neurite outgrowth and neurogenic-to-gliogenic competence ratio were significantly reduced in the patient-derived cells. As an underlying mechanism, we focused on the role of DGCR8 , a key gene for microRNA (miRNA) pro-cessing and mapped in the deleted region. In mice, Dgcr8 het-ero-knockout is known to show a similar phenotype of reduced neurosphere size. miRNA profiling detected reduced expression levels of miRNAs belonging to miR-17/92 cluster and miR-106a/b in the patient-derived neurospheres. Those miRNAs are reported to target p38 α , and conformingly the levels of p38 α were up-regulated in the patient-derived cells. p38 α is known to drive gliogenic differentiation. Inhibition of p38 activity by SB203580 in patient-derived neurospheres partially restored neurogenic competence. Furthermore, we confirmed an elevated expression of GFAP , a gliogenic (astrocyte) marker, in postmortem brains from schizophrenia patients. These results suggest that a dysregulated balance of neurogenic and gliogenic competences may underlie ‘general’ schizophrenia. Abstract Objective : There is evidence that tardive dyskinesia (TD) is associated with greater cognitive impairment. Patients with schizophrenia (SCZ) with TD (SCZ-TD + ) was reported to improve less than SCZ without TD (SCZ-TD¯) on some cognitive tests during treatment with antipsychotic drugs (APDs) other than clozapine (Caroff et al., J Clin Psychiatry, 2011). Clozapine improves some cognitive functions, especially, verbal fluency (VF). It improves working memory (WM) in the subset of patients who have higher N-desmethylclozapine (NDMC)/clozapine plasma ratio (Meltzer, Am J Psychiatry, 2015). However, overall, it worsens WM (Hagger et al., Biol Psychiatry, 1993). We have, now, examined the impact of TD on cognition after 6 wks of clozapine treatment, with special attention to WM and VF, along with assessments of the impact of clozapine and NDMC levels, and their ratio on cognition in a subsample. Methods : One hundred seventeen patients (24 SCZ-TD + ) were administrated a comprehensive cognitive, as well as psychopa-thology, assessments, at baseline and after 6 wks of clozapine Abstract So-called D-neuron (trace amine (TA) neuron) is the ligand neu-ron of trace amine-associated receptor, type 1 (TAAR1). Reduced stimulation of TAAR1 on dopamine (DA) neurons in the midbrain ventral tegmental area (VTA) has been revealed to increase firing frequency of VTA DA neurons. A Patent Cooperation Treaty (PCT)-required histochemical methods (K. Ikemoto) were used to specify subgroups of D-neurons in the human brain (Ikemoto et al. 1997, 2016 (in press)), and to show D-neuron decrease in the nucleus accumbens (Acc) (D16, subgroup of D-neurons) of postmortem brains with schizophrenia (Ikemoto et al. 2003). The human D-neuron system is found to be far developed in the forebrain in comparison with that of other species, includ-ing non-human primates (Kitahama et al.2009). TA decrease caused by D-neuron reduction, and consequent TAAR1 stimulation decrease on terminals of midbrain Abstract Small non-coding microRNA (miRNA) coordinate mRNA transla-tion in the brain, and their dysregulation has significant consequences in neurodevelopmental disorders. This hypothesis is supported by strong genetic evidence at the genome-wide associated variant in MIR137 (rs1625579) in recent PGC mega analysis of schizophrenia. We used a TaqMan genotyping and expression strategy to investigate the allelic expression (rs2660304) in postmortem DLPFC from subjects with schizophrenia and controls with no history of psychiatric disorder (n=74). While no significant difference was observed in the expression of miR-137